June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Evaluation of Filociclovir as a Potent Antiviral for Ocular Adenoviral Infections
Author Affiliations & Notes
  • Terry Bowlin
    Microbiotix, Inc., Worcester, Massachusetts, United States
  • Islam Hussein
    Microbiotix, Inc., Worcester, Massachusetts, United States
  • Eric G Romanowski
    Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Terry Bowlin, Microbiotix, Inc. (E), Microbiotix, Inc. (P); Islam Hussein, Microbiotix, Inc. (E), Microbiotix, Inc. (P); Eric Romanowski, Microbiotix, Inc. (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 422. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Terry Bowlin, Islam Hussein, Eric G Romanowski; Evaluation of Filociclovir as a Potent Antiviral for Ocular Adenoviral Infections. Invest. Ophthalmol. Vis. Sci. 2020;61(7):422.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is currently no approved antiviral treatment for adenoviral conjunctivitis, which is often associated with significant morbidity. These studies tested the antiviral activity of the novel broad-spectrum nucleoside analog, filociclovir (FCV), by determining the in vitro IC50 concentrations (concentrations that inhibit adenovirus plaque formation by 50%) of FCV and cidofovir (CDV), against a panel of seven (7) ocular adenovirus serotypes.

Methods : In vitro, the 50% inhibitory concentrations (IC50) of FCV and CDV were determined using standard plaque-reduction assays on A549 lung adenocarcinoma cells. Briefly, Ad3, Ad4, Ad5, Ad7a, Ad8, Ad19/64 and Ad37 were adsorbed on the A549 cells then treated with final concentrations of FCV and CDV of 100, 10, 1.0, 0.1, 0.01 and 0.001 µM and the antiviral activity of FCV and CDV were then quantified by plaque assay, done in triplicate.

Results : The mean in vitro IC50 for FCV ranged from 0.496 to 4.684 µM, whereas those for CDV ranged from 0.487 to 30.304 µM. FCV was more potent than CDV for five of the seven serotypes. See Table.

Conclusions : FCV demonstrated potent anti-adenovirus activity in vitro. Tolerability and efficacy studies after topical ocular administration in the rabbit eye model are currently underway to evaluate FCV as a topical antiviral treatment for ocular adenoviral infections.

This is a 2020 ARVO Annual Meeting abstract.

 

In vitro activity of filociclovir and cidofovir against a panel of 7 ocular adenovirus serotypes

In vitro activity of filociclovir and cidofovir against a panel of 7 ocular adenovirus serotypes

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×